Trial Profile
Phase II Neoadjuvant Study of EC followed by Abraxane in opetable breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin
- Indications Breast cancer
- Focus Therapeutic Use
- 19 Nov 2018 Status changed from recruiting to completed.
- 25 Jul 2014 New trial record